Both tools identify concordantly modifiable factors for MCI, which provide important evidence for establishing intervention measures.ĭementia is a leading cause of disability in people older than 65 years worldwide, including China, which induces huge challenges for policy makers, healthcare professionals, and family members. MCI prevalence is higher using MoCA compared to MMSE. MoCA is a better measure of cognitive function due to lack of ceiling effect and with good detection of cognitive heterogeneity. Increasing age (MMSE: OR = 2.073 for ≥75 years MoCA: OR = 1.869 for≥75 years), female (OR = 1.280 for MMSE OR = 1.163 for MoCA), living in county town (OR = 1.386 and 1.862 for MMSE and MoCA, respectively) or village (OR = 2.579 and 2.721 for MMSE and MoCA, respectively), smoking (OR = 1.373 and 1.288 for MMSE and MoCA, respectively), hypertension (MMSE: OR = 1.278 MoCA: OR = 1.208) and depression (MMSE: OR = 1.465 MoCA: OR = 1.350) were independently associated with greater likelihood of MCI compared to corresponding reference group in both scales (all p < 0.05). Percentage of relative standard deviation, the measure of inter-individual variance, for MoCA (26.9%) was greater than for MMSE (19.0%) overall ( p < 0.0001). Ceiling effect for MCI was less frequent using MoCA versus MMSE according to the distribution of total score. MMSE had good correlation with MoCA (Spearman correlation coefficient = 0.8374, p < 0.0001) and moderate agreement for detecting MCI with Kappa value of 0.5973 ( p < 0.0001). The overall MCI prevalence was 28.6% for MMSE and 36.2% for MoCA. Correlation and agreement for MCI between MMSE and MoCA were analyzed group differences in cognition were evaluated and multiple logistic regression model was used to clarify risk factors for MCI. Demographic and health-related characteristics were collected by questionnaires. Education-specific cutoffs of total score were used to diagnose MCI. Objective cognition was assessed by Chinese versions of MMSE and MoCA, and total score and subscores of cognitive domains were calculated for each. We conducted a cross-sectional analysis of 4923 adults aged ≥55 years from the Community-based Cohort Study on Nervous System Diseases. However, their comparison on which is best suited to assess cognition is scarce in samples from multiple regions of China. Early diagnosis allows the patient to adjust to the changes taking place, and take an role in their own treatment and plans for the future.The Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA) are the most commonly used scales to detect mild cognitive impairment (MCI) in population-based epidemiologic studies.Patients can only access drug and non-drug therapies after a diagnosis.Early therapeutic interventions can be effective in improving cognitive function and treating depression.In many cases, the earlier the diagnosis occurs, the better the outcome for the patient and their team. Dementia is a difficult medical challenge for the affected individual – and for their family and caregivers as well. Particularly for dementia, early diagnosis and treatment is an important factor driving patient success. The outcome is that patients are diagnosed with cognitive illness earlier and begin their treatment plan as soon as possible. It is effective for the accurate and early detection of cognitive dysfunction.It is administered quickly, in about 10 minutes. The MoCA test is a such an important tool for the treatment of cognitive illness because: The MoCA tests screens for the following illnesses and conditions: If you are concerned that you or someone you care about is showing early signs of cognitive decline, get in touch with our team today. Cognitive dysfunction can be one symptom of a wide range of illnesses – such as vascular illness or substance abuse. The test is 30 questions long and will take around 10 minutes to complete.Īnyone can take the MoCA test. The MoCA test is administered quickly and can be done either online (via Zoom or Skype) or in-person at our Etobicoke clinic. It is used in over 200 countries and has been translated to 65 different languages. The MoCA test has shown to be among the best screening tests for neurological and medical conditions in over 600 independent studies. MoCA is a leading tool for identifying cognitive dysfunction, enabling healthcare providers to immediately start the patient on a treatment plan if necessary. This cognitive screening test is the leading tool for the early and accurate detection of mild cognitive impairment and Alzheimer’s disease. At our Etobicoke clinic we administer the Montreal Cognitive Assessment Test – known as the MoCA test. Cognitive care, especially for our community’s seniors, is an important part of our mission at Mimico Medical.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |